Research Nester assesses the growth of global IBD (Ulcerative Colitis and Crohn’s Disease) treatment market over the forecast period, i.e., 2023-2033 and evaluates its future prospects. The rising prevalence of Crohn’s disease and increasing cases of IBD to drive market growth.
New York – October 10, 2022 – Research Nester’s recent market research analysis on “IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market: Global Demand Analysis & Opportunity Outlook 2033” delivers a detailed competitors analysis and a detailed overview of the global IBD (Ulcerative Colitis and Crohn’s Disease) treatment in terms of market segmentation by drug class, disease indication, distribution channel, and by region.
Growing Prevalence of Crohn’s Disease to Drive Growth of Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market
The global IBD (Ulcerative Colitis and Crohn’s Disease) treatment market is estimated to grow on account of the growing prevalence of Crohn’s disease across the world. As many as 780,000 people in the United States are affected by Crohn’s disease, making it a widespread ailment. The disease is most prevalent in people between the ages of 15 and 35, with 25% of cases being identified by age 20.
The market research report on global IBD (Ulcerative Colitis and Crohn’s Disease) treatment encompasses an in-depth analysis of the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends. These analyses help organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future. Additionally, the growth opportunities exposed by the market is poised to gain significant momentum in the next few years.
By distribution channel, the global IBD (Ulcerative Colitis and Crohn’s Disease) treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of these, the hospital pharmacies segment is estimated to hold the largest market share by the end of 2033 owing to rising patient flow in the hospitals. As per the health expenditure report, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000).
By region, the North America IBD (Ulcerative Colitis and Crohn’s Disease) treatment market is to generate the highest revenue by the end of 2033. The growth of the market can be attributed to the U.S. and Canada’s high prevalence and rising incidence of ulcerative colitis and Crohn’s disease. It was found during research that IBD, which includes Crohn’s disease and ulcerative colitis, has been identified in an estimated 3.1 million individuals (1.3%) in the United States.
The research is global in nature and covers detailed analysis on the IBD (Ulcerative Colitis and Crohn’s Disease) treatment market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising of global IBD (Ulcerative Colitis and Crohn’s Disease) treatment market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
This report also provides the existing competitive scenario of some of the key players of the global IBD (Ulcerative Colitis and Crohn’s Disease) treatment market which includes company profiling of Bristol Myers Squibb Company (BMS), Bausch Health Companies Inc., AbbVie Inc., Novartis AG, UCB, Inc., Biogen, Inc., Pfizer, Inc., Janssen Global Services, LLC, Takeda Pharmaceutical Company Limited, CELLTRION Inc., The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global IBD (Ulcerative Colitis and Crohn’s Disease) treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919